<SEC-DOCUMENT>0001213900-25-067663.txt : 20250725
<SEC-HEADER>0001213900-25-067663.hdr.sgml : 20250725
<ACCEPTANCE-DATETIME>20250725143104
ACCESSION NUMBER:		0001213900-25-067663
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250725
DATE AS OF CHANGE:		20250725

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Biofrontera Inc.
		CENTRAL INDEX KEY:			0001858685
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				473765675
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93395
		FILM NUMBER:		251151209

	BUSINESS ADDRESS:	
		STREET 1:		120 PRESIDENTIAL WAY,
		STREET 2:		SUITE 330
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		781-245-1325

	MAIL ADDRESS:	
		STREET 1:		120 PRESIDENTIAL WAY,
		STREET 2:		SUITE 330
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DEUTSCHE BALATON AKTIENGESELLSCHAFT
		CENTRAL INDEX KEY:			0001571071
		ORGANIZATION NAME:           	
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		ZIEGELHAUSER LANDSTRABE 1
		CITY:			HEIDELBERG
		STATE:			2M
		ZIP:			691924-0
		BUSINESS PHONE:		49 6221 64727-0

	MAIL ADDRESS:	
		STREET 1:		ZIEGELHAUSER LANDSTRABE 1
		CITY:			HEIDELBERG
		STATE:			2M
		ZIP:			691924-0
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: DEUTSCHE BALATON AKTIENGESELLSCHAFT -->
          <cik>0001571071</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>3</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <dateOfEvent>06/30/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001858685</issuerCIK>
        <issuerCUSIP>09077D209</issuerCUSIP>
        <issuerName>Biofrontera Inc.</issuerName>
        <address>
          <com:street1>120 Presidential Way,</com:street1>
          <com:street2>Suite 330</com:street2>
          <com:city>Woburn</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>01801</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Dr. Martin Flick</personName>
          <personPhoneNum>496221649240</personPhoneNum>
          <personAddress>
            <com:street1>Ziegelhaeuser Landstrasse 3</com:street1>
            <com:city>Heidelberg</com:city>
            <com:stateOrCountry>2M</com:stateOrCountry>
            <com:zipCode>69120</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Biofrontera AG</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>2M</citizenshipOrOrganization>
        <soleVotingPower>400000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>400000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>400000.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.23</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001571071</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Deutsche Balaton Aktiengesellschaft</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>2M</citizenshipOrOrganization>
        <soleVotingPower>58884.00</soleVotingPower>
        <sharedVotingPower>400000.00</sharedVotingPower>
        <soleDispositivePower>58884.00</soleDispositivePower>
        <sharedDispositivePower>400000.00</sharedDispositivePower>
        <aggregateAmountOwned>458884.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.86</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>VV Beteiligungen Aktiengesellschaft</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>2M</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>458884.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>458884.00</sharedDispositivePower>
        <aggregateAmountOwned>458884.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.86</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Delphi Unternehmensberatung Aktiengesellschaft</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>2M</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>458884.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>458884.00</sharedDispositivePower>
        <aggregateAmountOwned>458884.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.86</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Wilhelm Konrad Thomas Zours</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>2M</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>458884.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>458884.00</sharedDispositivePower>
        <aggregateAmountOwned>458884.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.86</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Alexander Link</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>2M</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>458884.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>458884.00</sharedDispositivePower>
        <aggregateAmountOwned>458884.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.86</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Hansjoerg Plaggemars</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>458884.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>458884.00</sharedDispositivePower>
        <aggregateAmountOwned>458884.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.86</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Pilar de la Huerta Martinez</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U3</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>400000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>400000.00</sharedDispositivePower>
        <aggregateAmountOwned>400000.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.23</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.001 per share</securityTitle>
        <issuerName>Biofrontera Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>120 Presidential Way,</com:street1>
          <com:street2>Suite 330</com:street2>
          <com:city>Woburn</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>01801</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>This Amendment No. 3 to Schedule 13D is being filed by Biofrontera AG ("BFAG"), Deutsche Balaton Aktiengesellschaft ("DB"), VV Beteiligungen Aktiengesellschaft ("VVB"), Delphi Unternehmensberatung Aktiengesellschaft ("DU"), Wilhelm Konrad Thomas Zours, Alexander Link, Hansjoerg Plaggemars and Pilar de la Huerta Martinez which are collectively referred to as the "Reporting Persons". BFAG, DB, VVB and DU are collectively referred to as the "Reporting Entities" and Messrs. Zours, Link and Plaggemars, and Mrs. Huerta Martinez are collectively referred to as the "Reporting Individuals".</filingPersonName>
        <principalBusinessAddress>The address of the principal business office of DB, VVB, DU, and Messrs. Zours, Link and Plaggemars is Ziegelhauser Landstrasse 3, Heidelberg, Germany, 69120. The address of the principal business office of BFAG and Mrs. Huerta Martinez is Hemmelrather Weg 201, D-51377 Leverkusen, Germany.</principalBusinessAddress>
        <principalJob>The principal business of VVB and DB is to invest in, hold and dispose of equity and equity-related investments.

The principal business of DU is to provide consulting services and to hold and dispose of equity and equity-related investments.

BFAG is a biopharmaceutical company specializing in the development and commercialization of pharmaceutical products for the treatment of dermatological diseases.

Wilhelm Konrad Thomas Zours, an individual, owns a majority interest in DU and is the sole member of the board of management of VVB and a member of the management board of DU (together with Hansjoerg Plaggemars).

Alexander Link is a member of the board of management of DB (together with Rolf Birkert), with single power of representation, and is a member and chair of the supervisory board of BFAG, with a casting vote.

Hansjoerg Plaggemars, an individual, is a member of the board of management of DU and is a member of the supervisory board of BFAG.

Pilar de la Huerta Martinez, an individual, is the sole member of the management board of BFAG.</principalJob>
        <hasBeenConvicted>During the past five years, none of the Reporting Persons has been, and to the knowledge of the Reporting Persons, none of the Scheduled Persons (as defined below) has been, convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).</hasBeenConvicted>
        <convictionDescription>During the past five years, none of the Reporting Persons has been, and to the knowledge of the Reporting Persons, none of the Scheduled Persons (as defined below) has been, party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</convictionDescription>
        <citizenship>The Reporting Entities are each organized under the laws of Germany. Each of the Reporting Individuals are citizens of Germany with the exception of Pilar de la Huerta Martinez, who is a citizen of Spain, and Hansjoerg Plaggemars, who is a citizen of USA.</citizenship>
      </item2>
      <item3>
        <fundsSource>Reference is made to Amendment No. 2 to Schedule 13D filed by BFAG, DB, VVB, DU, Mr. Zours, and Mr. Link on December 20, 2024. Since the date of such filing, none of the Reporting Persons named therein has acquired or disposed of any common stock of Biofrontera Inc.

As none of the Reporting Persons has made any acquisition of securities of the Issuer required to be reported under Regulation 13D-G, under the Securities Exchange Act of 1934, as amended (the "Act") (17 CFR 240.13d-1 through 240.13f-1), since the date of their last filing under Regulation 13D-G, this Item is inapplicable.

Notwithstanding the foregoing, On June 30, 2025, BFAG and its subsidiaries signed an agreement (the "Agreement") with the Issuer pursuant to which the Issuer acquired all rights in the United States (the "U.S. Rights") to Ameluz and RhodoLED. Pursuant to the Agreement, the Issuer will now pay a royalty of 12% in years where Ameluz revenue in the United States is less than $65.0 million and a royalty of 15% when Ameluz revenue in the United States exceeds $65.0 million. The royalty will replace the transfer pricing model under the Second Amended and Restated License and Supply Agreement effective as of February 13, 2024 by and among the Issuer, BFAG and BFAG's subsidiaries. In exchange for the U.S. Rights, in addition to the aforementioned royalty and an agreement to transfer all costs associated with the U.S. business, BFAG received 3,019 shares of the Issuer's Series D Convertible Preferred Stock, par value $0.001 per share (the "Series D Preferred Stock"). Each share of Series D Convertible Preferred Stock will have voting rights on an as-converted to common stock basis, and will be convertible at the option of BFAG into a number of shares of common stock of the Issuer equal to $1,000 divided by $0.6249, rounded down to the nearest whole share. Therefore, BFAG's 3,019 shares of Series D Preferred Stock will be convertible into 4,831,172 shares of the Issuer's common stock; provided however, that BFAG may not exercise such voting or conversion rights until the Issuer's stockholders approve the issuance of the Series D Preferred Stock and the shares of common stock issuable upon conversion thereof (the "Stockholder Approval").</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>Explanatory Note: There is no agreement among the Reporting Persons, written or oral, with respect to the acquisition, ownership, voting or disposition of any securities of the Issuer, and the Reporting Persons disclaim the existence of any group among them within the meaning of Section 13(d)(3) of the Act or the rules and regulations of the Securities and Exchange Commission ("SEC") promulgated thereunder. All percentages herein are based on 9,446,197 shares of common stock outstanding as reported by the Issuer as of May 13, 2025, in its Quarterly Report on Form 10-Q filed on May 15, 2025.

The information set forth in Item 3 of this Amendment No. 3 to Schedule 13D is hereby incorporated by reference into this Item 4.

Prior to November 2, 2021, the Issuer was a wholly owned subsidiary of BFAG. On November 2, 2021, the Issuer consummated its initial public offering ("IPO") of 3,600,000 units, each consisting of (i) one share of common stock of the Issuer and (ii) one warrant entitling the holder to purchase one share of the Issuer's common stock at an exercise price of $5.00 per share, and such equity securities were registered under Section 12(b) of the Act. Immediately following the IPO, BFAG owned 8,000,000 shares of common stock, or approximately 69.0% of the Issuer's then outstanding shares of common stock. According to the Issuer's publicly-available filings with the SEC, following the IPO, the Issuer entered into numerous transactions involving the issuance of Issuer equity securities and/or rights, resulting in substantial dilution to BFAG. In addition, according to such filings, effective as of 11:59 pm, July 3, 2023, the Issuer effected a 1-for-20 reverse stock split of its then outstanding shares of common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the 8,000,000 shares of Issuer common stock held by BFAG immediately following the IPO were converted into 400,000 shares of Issuer common stock. Other than the 3,019 shares of Series D Preferred Stock issued to BFAG pursuant to the Agreement, BFAG has not acquired any equity securities of the Issuer since the IPO. BFAG has not sold any equity securities of the Issuer since the IPO.

DB purchased the shares of common stock reported on this Amendment No. 3 to Schedule 13D for investment purposes. In addition, DB sought to offset in part the economic dilution resulting to BFAG (and, indirectly, to BFAG's shareholders) as a result of the Issuer's repeated issuances of common stock and warrants, as described in the Issuer's publicly-available filings with the SEC. As a result of the Reverse Stock Split, the 1,177,680 shares of common stock of the Issuer purchased by DB were converted into 58,884 shares of common stock.

Subject to market conditions, DB currently intends to acquire additional voting securities of the Issuer, or instruments convertible into voting securities of the Issuer, as DB may from time to time deem desirable for investment purposes. Any such acquisitions may be effected through open market purchases, block trades, privately-negotiated transactions, subscriptions made pursuant to rights offerings by the Issuer, or otherwise (including the exercise of any options or other securities exercisable for, or convertible into, any such securities of the Issuer).

Subject to market conditions, DB may also dispose of voting securities of the Issuer from time to time, as DB deems desirable. Any such dispositions may be effected through open market sales, block trades, privately-negotiated transactions, or otherwise.

On December 13, 2021, DB filed an action against BFAG with the local court of Cologne, Germany. DB argues that the listing of the common stock by the Issuer on NASDAQ and the issuance of common stock to third parties as part of the IPO required approval at BFAG's general meeting. The local court of Cologne ruled that BFAG's board resolutions regarding the IPO of the Issuer are void because BFAG had to obtain its general meeting's approval. However, the former board members and members of the supervisory board of BFAG joined the litigation and lodged an appeal against such ruling to the Higher Regional Court of Cologne, Germany. The Higher Regional Court of Cologne, Germany rejected the litigation but permitted the appeal to the Federal Supreme Court. DB has not yet taken a decision on whether it will go to the Federal Supreme Court in this particular case.

The Reporting Individuals, DU and VVB currently do not intend to acquire securities of the Issuer directly.

BFAG, except for its contingent right to convert its shares of Series D Preferred Stock into shares of the Issuer's common stock, which it may do at any time upon the Issuer's receipt of the Stockholder Approval, does not currently intend to acquire additional securities of the Issuer directly. Additionally, pursuant to the Agreement, effective as of June 30, 2025 and for three years following such date, for so long as BFAG holds any shares of Series D Preferred Stock, or any shares of common stock issued upon the conversion of shares of Series D Preferred Stock, BFAG shall have the right to appoint one member of the Issuer's board of directors if the board of directors consists of up to seven members, and two members if the board of directors consists of eight or more members.

Except as set forth above, the Reporting Persons have no current plans or proposals with respect to (i) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (ii) any extraordinary corporate transaction, such as a merger, reorganization, or liquidation, involving the Issuer or any of its subsidiaries, (iii) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries, (iv) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (v) any material change in the present capitalization or dividend policy of the Issuer; (vi) any other material change in the Issuer's business or corporate structure, (vii) changes to the Issuer's organizational documents or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (viii) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (ix) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the Act; or (x) any action similar to any of the foregoing.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>The beneficial ownership of each of the Reporting Persons in the shares of the Issuer's common stock to which this statement relates is as follows:

BFAG holds 400,000 shares of the Issuer's common stock, which constitutes 4.23% of the beneficial ownership of the shares of the Issuer's common stock.

DB beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG. DB, directly and indirectly through certain of its subsidiaries, holds 42.6% of the outstanding voting shares in BFAG and, as of June 12, 2024, consolidates BFAG for financial reporting purposes. Mr. Link, a management board member of DB, is a member and serves as chairman of the supervisory board of BFAG. As chairman, Mr. Link is entitled to the casting vote in the event that any vote of the supervisory board would otherwise result in a tie. In addition, two other supervisory board members of BFAG, Mr. Hansjorg Plaggemars and Mr. Tobias Reich, serve as management board members of certain subsidiaries of DB. As a result of such stock ownership and relationships, DB may be deemed to have shared voting power and/or shared dispositive power over the shares of the Issuer held by BFAG. However, DB disclaims beneficial ownership of the shares of the Issuer held by BFAG.

VVB beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG, which may be deemed to be beneficially owned by DB. VVB owns a majority interest in DB, and therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. However, pursuant to a non-domination agreement between VVB and DB (the "Non-Domination Agreement"), VVB has agreed that it cannot exercise voting control (through voting more than 45%, directly or indirectly, of the shares) over DB. Accordingly, VVB disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB (whether directly or through BFAG) in excess of 45% of the voting power thereof.

DU beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG, which may be deemed to be beneficially owned by DB. DU owns a majority interest in VVB, which owns a majority interest in DB, and therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. However, based on the Non-Domination Agreement between VVB and DB, DU disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB in excess of 45% of the voting power thereof. Note that, in addition to the voting shares in BFAG held by DB and its subsidiaries, DU directly holds a 19.6% voting interest in BFAG. Accordingly, disregarding the effect of the Non-Domination Agreement, DU, VVB and DB collectively hold 62.2% of the outstanding voting stock of BFAG and therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer held by BFAG. DU disclaims beneficial ownership of the shares of the Issuer beneficially owned by BFAG.

Wilhelm Konrad Thomas Zours beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG, which may be deemed to be beneficially owned by DB. Mr. Zours owns a majority interest in DU and is the sole member of the management board of VVB and - together with Mr. Plaggemars - board member of DU, and in such roles therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. Based on the Non-Domination Agreement, Mr. Zours disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB in excess of 45% of the voting power thereof. Mr. Zours further disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB and/or BFAG, except to the extent of his pecuniary interest therein. Mr. Zours does not own any shares of the Issuer in his individual capacity.

Alexander Link beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG. Mr. Link is a member of the management board of DB and in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. Mr. Link is also a member and chairman of the supervisory board of BFAG and in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by BFAG. Mr. Link disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB and/or BFAG. Mr. Link does not own any shares of the Issuer in his individual capacity.

Hansjoerg Plaggemars beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG, which may be deemed to be beneficially owned by DB. DU owns a majority interest in VVB, which owns a majority interest in DB, and therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. Mr. Plaggemars is a member of the management board of DU, and in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. Mr. Plaggemars is also a member of the supervisory board of BFAG, in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by BFAG. Mr. Plaggemars disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB and/or BFAG. Mr. Plaggemars does not own any shares of the Issuer in his individual capacity.

Pilar de la Huerta Martinez beneficially owns 400,000 shares of the Issuer's common stock, which constitutes 4.23% of the aggregate beneficial ownership of such class. The 400,000 shares beneficially owned consists of the 400,000 shares held by BFAG. Mrs. Huerta Martinez is the sole member of the management board of BFAG, and in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by BFAG. Mrs. Huerta Martinez disclaims beneficial ownership of the shares of the Issuer beneficially owned by BFAG. Mrs. Huerta Martinez does not own any shares of the Issuer in her individual capacity.

For the reasons set forth above, the Reporting Persons may be deemed to constitute a group under Section 13(d)(3) of the Act, but each disclaim existence of any such group.

All percentages relating to the Issuer's common stock set forth in this Amendment No. 3 to Schedule 13D are based on 9,446,197 shares of common stock outstanding as reported by the Issuer as of May 13, 2025, in its Quarterly Report on Form 10-Q filed on May 15, 2025.</percentageOfClassSecurities>
        <numberOfShares>(i) BFAG has sole power to vote or direct the vote of, and sole power to dispose or direct the disposition of 400,000 shares of the Issuer's common stock. BFAG does not have shared power to vote or direct the vote of, or shared power to dispose or direct the disposition of, any shares of the Issuer's common stock.

(ii) DB has sole power to vote or direct the vote of, and sole power to dispose or direct the disposition of 58,884 shares of the Issuer's common stock. DB has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 400,000 shares.

(iii) VVB does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, VVB has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(iv) DU does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, DU has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(v) Mr. Zours does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, Mr. Zours has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(vi) Mr. Link does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, Mr. Link has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(vii) Mr. Plaggemars does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, Mr. Plaggemars has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(viii) Mrs. Huerta Martinez does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, Mrs. Huerta Martinez has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 400,000 shares of the Issuer's common stock.</numberOfShares>
        <transactionDesc>During the 60 day period preceding the date of this filing, the Reporting Persons have not purchased or sold any shares of common stock of the Issuer. However, as described above, during the 60 day period preceding the date of this filing, BFAG has acquired 3,019 shares of the Issuer's Series D Preferred Stock.</transactionDesc>
        <listOfShareholders>Not applicable.</listOfShareholders>
        <date5PercentOwnership>Each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the Issuer's common stock by reason of the Issuer's repeated issuances of common stock and warrants, as described in the Issuer's publicly-available filings with the SEC, based on 9,446,197 shares of common stock outstanding as reported by the Issuer as of May 13, 2025, in its Quarterly Report on Form 10-Q filed on May 15, 2025. However, the Reporting Persons expect to again become the beneficial owners of more than five percent of the Issuer's common stock upon the Issuer's receipt of the Stockholder Approval because, upon such receipt of the Stockholder Approval, BFAG's 3,019 shares of Series D Preferred Stock will become immediately convertible into 4,831,172 shares of the Issuer's common stock.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>None.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>99.1 - Joint Filing Agreement
99.4 - Power of Attorney</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Biofrontera AG</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Pilar de la Huerta Martinez</signature>
          <title>Pilar de la Huerta Martinez, Chief Financial Officer</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Deutsche Balaton Aktiengesellschaft</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Rolf Birkert</signature>
          <title>Rolf Birkert</title>
          <date>07/25/2025</date>
        </signatureDetails>
        <signatureDetails>
          <signature>/s/ Alexander Link</signature>
          <title>Alexander Link</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>VV Beteiligungen Aktiengesellschaft</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Wilhelm Konrad Thomas Zours</signature>
          <title>Wilhelm Konrad Thomas Zours</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Delphi Unternehmensberatung Aktiengesellschaft</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Wilhelm Konrad Thomas Zours</signature>
          <title>Wilhelm Konrad Thomas Zours</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Wilhelm Konrad Thomas Zours</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Wilhelm Konrad Thomas Zours</signature>
          <title>Wilhelm Konrad Thomas Zours</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Alexander Link</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Alexander Link</signature>
          <title>Alexander Link</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Hansjoerg Plaggemars</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Hansjoerg Plaggemar</signature>
          <title>Hansjoerg Plaggemars</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Pilar de la Huerta Martinez</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Pilar de la Huerta Martinez</signature>
          <title>Pilar de la Huerta Martinez</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>ea025026301ex1_bio.htm
<DESCRIPTION>SCHEDULE 1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Members of Management of the Reporting Entities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The members of the supervisory board of BFAG are
Alexander Link (chairman), Helge Lubenow (deputy Chairman), Hansj&ouml;rg Plaggemars, Tobias Reich, Karlheinz Schmelig and Heikki Lanckriet.
The sole member of the executive board of BFAG is Pilar de la Huerta Martinez.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The members of the management board of DB are Rolf Birkert and Alexander
Link and members of the supervisory board of DB are Wilhelm Konrad Thomas Zours, Dr Burkhard Schaefer and Mr. Philip Hornig. The sole
member of the management board of VVB is Mr. Zours.&nbsp; The members of the supervisory board of VVB are Philip Hornig, Burkhard Schaefer
and Harald Schaefer. &nbsp;The members of the management board of DU are Mr. Zours and Mr. Plaggemars.&nbsp; The members of the supervisory
board of DU are Karin Lergenmueller, Philip Hornig, and Burkhard Schaefer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the name, present occupation or employment
and citizenship of each such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; border-bottom: black 1.5pt solid; text-align: left; width: 10%; vertical-align: bottom"><B>Name</B></TD>
    <TD STYLE="text-align: center; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 20%; vertical-align: bottom"><B>Present<BR>
Business&nbsp;Address</B></TD>
    <TD STYLE="text-align: center; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 55%; vertical-align: bottom"><B>Present Occupation</B></TD>
    <TD STYLE="text-align: center; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 12%; vertical-align: bottom"><B>Citizenship</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Rolf Birkert</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor; Member of the Management Board of DB</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Management Board of Deutsche Balaton Biotech AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Management Board of Pflege.Digitalisierung Invest AG</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Management Board of Latonba AG</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Management Board of Talbona AG;<BR>
    Managing Director of BB19 Unternehmensberatung UG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director of BB96 Beteiligungen GmbH;</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Alexander Link</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor; Member of the Management Board of DB;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-Executive Director of 4basebio PLC;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supervisory Board member and chairman of BFAG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supervisory Board member and chairman of SPK S&uuml;ddeutsche Privatkapital
    AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supervisory Board member and chairman of SPARTA Invest AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of Epigenomics AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of bioXXmed AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of MISTRAL Media AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of CARUS AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of DIO Deutsche Immobilien Opportunit&auml;ten
    AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of Nestmedic S.A.</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Wilhelm Konrad Thomas Zours</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor; sole Member of the Management Board of VVB; Member of the
    Management Board of DU;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board and chairman of DB;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board and deputy chairman of Beta Systems
    Software AG</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Hansj&ouml;rg Plaggemars</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of BFAG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Board of 2invest AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Management Board of Altech Advanced Materials AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Executive Board of Epigenomics AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Management Board of DU;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Management Board of Heidelberger Beteiligungsholding
    AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-executive Director of GeoPacific Resources Ltd;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-executive Director of 4basebio PLC;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-executive Director of Wiluna Mining Corporation;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-executive Director of Altech Batteries Limited;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-executive Director of Patronus Resources Limited;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Management Board of Strawtec Group AG</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Liquidator of Alpha Cleantec AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director of KiCo Invest GmbH;<BR>
    Managing Director of BALATON Estate Ltd;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director of BALATON Great Lakes Ltd.</P></TD>
    <TD>&nbsp;</TD>
    <TD>USA</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Tobias Reich</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>Member of the Supervisory Board of BFAG; Chief Executive Officer and Member of the Board of ConBrio Beteiligungen AG.</TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Helge Lubenow</B></TD>
    <TD>&nbsp;</TD>
    <TD>Hemmelrather Weg 201, D-51377 Leverkusen, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of BFAG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member and chairwoman of the supervisory board of Epigenomics AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer of Epignostix GmbH</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Heikki Lanckriet</B></TD>
    <TD>&nbsp;</TD>
    <TD>Hemmelrather Weg 201, D-51377 Leverkusen, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of BFAG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer of 4basebio PLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Board of Directors of Biofrontera Inc.</P></TD>
    <TD>&nbsp;</TD>
    <TD>Belgium</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Mr. Karlheinz Schmelig</B></TD>
    <TD>&nbsp;</TD>
    <TD>Hemmelrather Weg 201, D-51377 Leverkusen, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of BFAG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing partner of Creathor Ventures Management GmbH</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Ms. Pilar de la Huerta Martinez</B></TD>
    <TD>&nbsp;</TD>
    <TD>Hemmelrather Weg 201, D-51377 Leverkusen, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer/Managing Director of BFAG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sole Member of the Executive Board of BFAG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing director of Biofrontera Bioscience GmbH;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing director of Biofrontera PHARMA GmbH;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing director of Biofrontera Development GmbH;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing director of Biofrontera Neuroscience GmbH;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director of Biofrontera UK Ltd.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Board of Directors of Vaxdyn S.L.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Board of Directors of Epidisease S.L.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Board of Directors of Creatsens Health</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Board of Directors of CELAX Innovation S.L.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Board of Directors Sarcorem S.L.</P></TD>
    <TD>&nbsp;</TD>
    <TD>Spain</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Ms. Karin Lergenmueller</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member and chairman of the Supervisory Board of DELPHI Unternehmensberatung
    Aktiengesellschaft;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member and chair(wo)man of the Supervisory Board of Alpha Cleantec
    AG i. L.;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of Deutsche Balaton Biotech AG;</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Mr. Philip Hornig</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of DELPHI Unternehmensberatung Aktiengesellschaft
    and of VV Beteiligungen Aktiengesellschaft;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of DB;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member and chairman of the Supervisory Board of capFlow AG i.L.;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of SPK S&uuml;ddeutsche Privatkapital
    AG;</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Mr. Burkhard Schaefer</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of DU and VV Beteiligungen Aktiengesellschaft;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of DB;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member and chairman of the Supervisory Board of Altech Advanced Materials
    AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member and chairman of the Supervisory Board of MISTRAL Media AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of Alpha Cleantec AG i.L.;</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Mr. Harald Schaefer</B></TD>
    <TD>&nbsp;</TD>
    <TD>Ziegelhaeuser Landstrasse 3,<BR>
69120 Heidelberg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member and chairman of the Supervisory Board of VV Beteiligungen Aktiengesellschaft;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member and chairman of the Supervisory Board of Rostra AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">supervisory board member and chairman of Strawtec Group AG;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Supervisory Board of SPK S&uuml;ddeutsche Privatkapital
    AG</P></TD>
    <TD>&nbsp;</TD>
    <TD>Germany</TD></TR>
  </TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea025026301ex99-1_bio.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JOINT FILING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned acknowledge and agree that the
foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement
on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy
of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of
the information concerning the others, except to the extent that he, she or it knows or has reason to believe that such information is
inaccurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>Date: July 25, 2025</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B><U>BIOFRONTERA AG</U></B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><B>/s/ </B>Pilar de la Huerta Martinez</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD> Pilar de la Huerta Martinez</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B><U>DEUTSCHE BALATON AKTIENGESELLSCHAFT</U></B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> /s/ Alexander Link</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Alexander Link</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> <B>/</B>s/ Rolf Birkert&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Rolf Birkert</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B><U>VV BETEILIGUNGEN AKTIENGESELLSCHAFT</U></B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>&nbsp;</B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>/s/ </B>Wilhelm Konrad Thomas Zours</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Wilhelm Konrad Thomas Zours&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase; background-color: white"><B><U>Delphi Unternehmensberatung<BR>
 Aktiengesellschaft</U></B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>&nbsp;</B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>/s/ </B>Wilhelm Konrad Thomas Zours</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Wilhelm Konrad Thomas Zours</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B><U>ALEXANDER LINK</U></B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Alexander Link</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B><U>Wilhelm Konrad Thomas Zours</U></B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>/s/ </B>Wilhelm Konrad Thomas Zours</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B><U>Hansjoerg Plaggemars</U></B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> <B>/s/ </B>Hansjoerg Plaggemar</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B><U>Pilar de la Huerta Martinez</U></B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> <B>/s/ </B>Pilar de la Huerta Martinez</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>4
<FILENAME>ea025026301ex99-4_bio.htm
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>KNOW ALL MEN BY THESE PRESENTS</B>, that the
undersigned each hereby constitutes and appoints <B>Philipp Wiedmann, Dr. Martin Flick </B>and <B>Alexander Link</B>, and each of them
separately and singly, his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates
and documents that may be necessary, desirable or appropriate to be executed on behalf of the undersigned as an individual or in the undersigned&rsquo;s
capacity as an officer, director, board member, or other representative, as applicable, of any corporation, limited liability company
or other entity, pursuant to the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment
Company Act of 1940, and the Investment Advisers Act of 1940, in each case as amended from time to time, and any and all rules and regulations
of the United States Securities and Exchange Commission promulgated thereunder, or pursuant to any U.S. state securities or &ldquo;blue
sky&rdquo; law, or the rules of any U.S. national securities exchange, registered securities association, or other self-regulatory organization
(collectively, &ldquo;<U>U.S. Securities Laws and Rules</U>&rdquo;), under seal or otherwise, and to acknowledge and file or furnish the
same, with all exhibits thereto, and any other documents in connection therewith, with the United States Securities and Exchange Commission,
and with any other entity, when and if such execution, acknowledgment, and filing or furnishing is mandated by the U.S. Securities Laws
and Rules, or any of them, as applicable, granting unto said attorney-in-fact the full power and authority to do and perform each and
every act and thing necessary, desirable or appropriate, to fulfill the foregoing purposes, to the full extent that the undersigned might
or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to
be done by virtue hereof. The above-named attorneys-in-fact and their substitutes shall have no liability to the undersigned or any such
corporation, limited liability company or other entity for any liability, cost, or damage incurred by any such attorney-in-fact or his
substitutes, and shall be indemnified and held harmless for the same, absent willful misconduct or gross negligence, provided that no
such person shall be indemnified for any such liability, cost or damage resulting from any violation of U.S. Securities Laws and Rules
by such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, this Power of Attorney
has been signed as of the 25th day of July, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Hansjoerg Plaggemars</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Hansjoerg Plaggemars</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Pilar de la Huerta Martinez</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Pilar de la Huerta Martinez</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
